/

SCYX

SCYNEXIS, Inc.Closed

3.99−0.04 −0.99%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

4.03

Prev close

4.03

Day range

3.924.09

52-week range

3.539.12

Volume

66.75K0.24×

Mkt cap

39.70M

P/E ttm

—

Fwd P/E

-1.72

EPS ttm

-0.8900

Div yield

0.00%

Earnings

—

From 52w high

−56.25%

Price Chart

Yahoo Finance · delayed

SCYXOct 13, 2026O 4.03H 4.09L 3.92C 3.99−0.04 (−0.99%)Vol 66.70K

SMA 504.90
SMA 2005.63

1Y change −38.58% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

SCYX SCYNEXIS, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −17.56%
1 month: −17.56%
3 months: −19.07%
6 months: −51.10%
Year to date: −21.08%
1 year: −38.58%

Valuation & ownership

Market cap: 39.70M
Enterprise value: −12.44M
P/E (ttm): —
Forward P/E: -1.72
PEG ratio: —
Price / book: 0.59
Price / sales (ttm): 2.07
EV / EBITDA: —
EPS (ttm): -0.8900
EPS (forward): -2.32
Beta (5y monthly): 1.06
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 9.95M
Float: 7.35M
Short % of float: 6.09%
Short ratio (days): 1.34
Held by insiders: 2.05%
Held by institutions: 62.10%
Avg volume (3m): 282.53K
50-day average: 4.92
200-day average: 5.63
52-week change: −38.58%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 36.5
vs 50-day SMA: −18.61%
vs 200-day SMA: −29.10%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 9.48%
Realised vol (20d, ann.): 88.1%
From 52-week high: −56.25%
From 52-week low: +13.03%

ANR

Analyst Consensus

3 analysts

Consensus

Strong buy

1.33 on a 1 (strong buy) – 5 (sell) scale

Mean target

36.33

+810.61% implied

Low 32.00Median 33.00High 44.00

Recommendation trend

Now3 / 0 / 0
1m ago3 / 0 / 0

DES

About SCYNEXIS, Inc.

Yahoo Finance profile

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 18
Headquarters: Jersey City, NJ, United States
Website: scynexis.com
Officers: Dr. David Gonzalez Angulo M.D. CEO, President & Director
Mr. Scott Sukenick J.D. Chief Legal Officer & Corporate Secretary
Mr. Sanjay S. Subramanian M.B.A., M.S. Chief Financial Officer
Ms. Daniella Gigante Vice President of Human Resources & Information Technology

SEAS

Seasonality · SCYX

2014–2026 · monthly returns

Strongest month Nov +10.62%Weakest month Jun −7.93%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	12.5	5.5	22.3	1.4	-24.2	-27.8	18.9	8.1	-5.5	-19.2			−21.1%
2025	-11.6	-3.7	-7.6	3.8	-11.4	-22.9	2.2	20.4	-7.3	-14.3	4.5	-8.4	−47.8%
2024	-7.6	-21.4	-9.3	15.0	42.9	-17.2	6.5	-31.5	2.1	-8.7	0.7	-11.7	−45.7%
2023	17.6	-18.8	101.3	5.0	-20.6	18.0	0.0	19.3	-35.2	-17.1	-11.1	32.7	+42.9%
2022	-19.7	-14.7	-6.5	-31.7	-21.0	-11.8	24.2	9.5	-5.1	-3.8	2.2	-33.9	−74.4%
2021	-2.4	4.1	2.1	-4.8	26.7	-23.2	-5.3	-6.5	-18.7	-5.5	47.3	-17.3	−20.3%
2020	-5.2	8.7	-16.7	23.6	-21.9	-0.4	-13.7	-12.8	-21.9	-0.9	52.2	15.0	−15.9%
2019	111.6	20.6	22.8	3.3	-21.2	6.5	-14.5	-1.8	-3.2	9.9	-7.7	-15.7	+88.8%
2018	-23.3	-7.9	-18.3	-11.9	52.5	-8.9	-3.0	-15.1	-11.1	-16.7	-26.0	-34.9	−79.2%
2017	-5.3	9.3	-16.4	0.7	-42.8	12.6	-3.9	11.6	25.5	-17.8	0.5	16.6	−27.3%
2016	-26.4	7.2	-17.8	-3.0	1.0	-45.1	-6.9	43.1	33.9	-17.1	19.9	-17.1	−48.6%
2015	8.0	-8.2	-16.2	12.4	-7.4	1.7	-9.6	-6.0	-2.5	-12.2	6.1	-8.4	−37.8%
2014						-4.5	-13.0	-1.0	6.9	9.2	38.8	-10.9	+18.8%

INSD

Insider Activity · SCYX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

3.64M shares

Sells, 6 months

599K shares

Net shares

+3.04M

Net change in insider shares

−107.20%

Date	Insider	Transaction	Shares	Value
Sep 17, 2026	Burke Steven KeithDirector	Stock Award(Grant) at price 0.00 per share.	5.8K	—
Jun 25, 2026	Tinmouth Brian PhilippeDirector	Stock Award(Grant) at price 0.00 per share.	2.9K	—
Jun 25, 2026	Anido ArmandoDirector	Stock Award(Grant) at price 0.00 per share.	2.9K	—
Jun 25, 2026	Hastings David CDirector	Stock Award(Grant) at price 0.00 per share.	2.9K	—
Jun 25, 2026	Hanham Ann FDirector	Stock Award(Grant) at price 0.00 per share.	2.9K	—
Jun 25, 2026	Macdonald GuyDirector	Stock Award(Grant) at price 0.00 per share.	2.9K	—
Mar 31, 2026	Angulo Gonzalez DavidChief Executive Officer	—	108.7K	—
Jan 28, 2026	Sukenick ScottOfficer	—	129.8K	—
Jan 28, 2026	Macleod IvorChief Financial Officer	—	129.8K	—
Jan 28, 2026	Angulo Gonzalez DavidChief Executive Officer	—	391.3K	—
Oct 16, 2025	Angulo Gonzalez DavidChief Executive Officer	Stock Award(Grant) at price 0.76 per share.	32.5K	$24.70K
Jun 25, 2025	Tinmouth Brian PhilippeDirector	—	23K	—
Jun 25, 2025	Anido ArmandoDirector	—	23K	—
Jun 25, 2025	Hastings David CDirector	—	23K	—
Jun 25, 2025	Hanham Ann FDirector	—	23K	—
Jun 25, 2025	Macdonald GuyDirector	—	23K	—
Jun 25, 2025	Gilman Steven CDirector	—	23K	—
Apr 8, 2025	Angulo Gonzalez DavidChief Executive Officer	Stock Award(Grant) at price 0.84 per share.	23K	$19.32K
Mar 19, 2025	Angulo Gonzalez DavidChief Executive Officer	Stock Award(Grant) at price 1.05 - 1.07 per share.	18.8K	$19.84K
Jan 22, 2025	Sukenick ScottOfficer	—	92.5K	—

13F

Investors Holding SCYX

latest 13F filings of 29 followed managers

Investors holding SCYX
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$311.5K	0.00%	76.53K	New	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

SCYX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

SCYX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About SCYNEXIS, Inc.

Seasonality · SCYX

Insider Activity · SCYX

Congress Trades · SCYX

Investors Holding SCYX

Investors Holding SCYX

Congress Trades · SCYX

Insider Activity · SCYX

Seasonality · SCYX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About SCYNEXIS, Inc.

Financial Snapshot

Earnings & Dividends

News